

**Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase I and Review of New Drugs
Pharmacy and Therapeutics Committee Meeting
Monday, October 23, 2006
9:00 a.m., 7th Floor Conference Rooms
DRAFT AGENDA**

**Welcome and Comments from
DMAS' Director**

**Patrick Finnerty,
DMAS Director**

Comments from the Chairperson

**Randy Axelrod, M.D.,
Chairman**

**Acceptance of Minutes From
March 30, 2006 P&T Meeting**

P&T Committee Members

**Status of Long Acting Narcotics
Prior Authorizations**

**Patrick Finnerty,
DMAS Director**

Drug Class Discussions

P&T Committee Members

Review of New Drugs in PDL Phase II

- Daytrana® -- CNS Stimulants/ADHD
- Azithromycin -- Macrolide
- Clarithromycin -- Macrolide
- Zaditor -- Ophthalmic Antihistamines
- Ketotifen Fumerate -- Ophthalmic Antihistamines

Phase I PDL Annual Review

- | | |
|--|--|
| • HMG CoA Reductase Inhibitors (Statins) | • H2 Antagonists |
| • Cox-2 Inhibitors | • Second Generation Antihistamines (LSAs) |
| • Proton Pump Inhibitors (PPIs) | • Benzodiazepine Sedative Hypnotics
(formerly included with Sedative Hypnotics) |
| • Angiotensin Receptor Blockers
(formerly Angiotensin Receptor Antagonists) | • Other Sedative Hypnotics
(formerly included with Sedative Hypnotics) |
| • Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors) | • Electrolyte Depleters |
| • Inhaled Corticosteroids | • Urinary Tract Antispasmodics |
| • Nasal Steroids | • Topical Immunomodulators |
| • Beta Adrenergics | • Lipotropics Non-Statins: Fibric Acid |
| • COPD- Anticholinergics
(formerly included with Beta Adrenergics) | • Lipotropics Non-Statins: Niacin Derivatives |
| • Beta Blockers | • Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension |
| • Calcium Channel Blockers | |

Confidential Meeting

**Confidential Meeting for
P&T Committee Members,
DMAS, and FHSC Pursuant
to 42 U.S.C. § 1396r-8 to
discuss pricing information**

**Criteria Discussion of Phase II
New Drugs***

P&T Committee Members

**Criteria Discussions for PDL Phase I
Drug Classes***

P&T Committee Members

Next Meeting – Spring 2007

**Randy Axelrod, M.D.,
Chairman**

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase I annual review and specific new drugs in PDL Phase II classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase I Annual Review – October 2005 to present
- New Drugs in PDL Phase II Drug Classes – March 2005 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmass.virginia.gov by COB Monday, October 9, 2006.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by COB Monday, October 9, 2006.